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Background: Patients with atrial ﬁbrillation (AF) may beneﬁt from undergoing concomitant interventions
of left atrial catheter ablation and device occlusion of the left atrial appendage (LAA) as a two-pronged
strategy for rhythm control and stroke prevention. We report on the outcome of combined procedures in
a single center case series over a 5-year timeframe.
Methods: Ninety-eight patients with non-valvular AF and a mean CHA2DS2-VASc score 2.671.0 under-
went either ﬁrst time, or redo pulmonary vein isolation (PVI) procedures, followed by successful implant
of a Watchmans device.
Results: All procedures were generally uncomplicated with a mean case time of 213740 min. Complete
LAA occlusion was achieved at initial implant in 92 (94%) patients. Satisfactory LAA occlusion was
achieved in 100% of patients at 12 months, with a complete LAA occlusion rate of 86%. All patients
discontinued oral anticoagulation. Persistent late peri-device leaks were more frequently associated with
device angulation or shoulder protrusion, and were associated with a signiﬁcantly lower achieved device
compression of 1273% vs. 1575% (po0.01) than complete occlusion. One ischemic stroke was recorded
over a mean follow-up time of 8027439 days. Twelve months' freedom from detectable AF was
achieved in 77% of patients.
Conclusions: Combined procedures of catheter ablation for AF and Watchmans LAA implant appear to be
feasible and safe, with excellent rates of LAA occlusion achieved and an observed stroke rate of 0.5% per
year during mid-term follow-up. Incomplete occlusion was associated with lower achieved device
compression and was more frequently associated with suboptimal device position.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Left atrial appendage (LAA) occlusion with the Watchmans
device (Boston Scientiﬁc, Natick, USA) has demonstrated efﬁcacy
in long term stroke prevention for patients with non-valvular
atrial ﬁbrillation (AF) with a CHADS2 score Z1 and a demon-
strated mortality beneﬁt compared with warfarin [1]. Catheter
ablation therapy for AF is an efﬁcacious rhythm control strategy
for patients with symptomatic, drug-refractory AF [2], but its role
in long-term stroke prevention remains unproven. Evidence sug-
gests that longer term AF recurrence rates, following initially
successful catheter ablation are signiﬁcant [3], and that oral
anticoagulation cannot be safely stopped in patients with a
CHA2DS2-VASc stroke risk score of Z2 [4]. Both proceduresblished by Elsevier B.V. This is an
list Centre, Newdegate St,
lia. Tel.: þ61 7 3394 3100;
u (K.P. Phillips).require percutaneous catheter instrumentation of the left atrium.
Therefore, a subset of patients with symptomatic AF may beneﬁt
from undergoing concomitant intervention of catheter ablation
and device occlusion of the LAA [5] as a two-pronged strategy for
rhythm control and stroke prevention. We report on the outcome
of combined procedures with the Watchmans device in a single
center over a 5-year timeframe.2. Material and methods
In December 2009, following Therapeutic Goods Administra-
tion approval of the Watchmans device in Australia, patients with
a CHADS2 score of 1 or greater (PROTECT AF inclusion criteria [1]),
seeking to undergo left atrial catheter ablation for symptomatic,
drug-refractory non-valvular AF at a single center, were offered
concomitant implant as an alternative to taking long-term oral
anticoagulation. Subsequent to the updated ESC Clinical Guide-
lines for the Management of Atrial Fibrillation in 2010 [6], aopen access article under the CC BY-NC-ND license
Fig. 1. Internal view of LAA ostium (outlined in yellow) from cardiac CT recon-
struction (right lateral view) with schemata of approximate measurement angles
during multiplane TOE for 0°, 45°, 90° and 135°. Labels indicate LSPV (left superior
pulmonary vein) and LIPV (left inferior pulmonary vein).
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retrospective study was approved by the institutional review
board for human research and complies with the Declaration of
Helsinki. Informed consent was obtained from all participants.
2.1. Procedural planning
Patients underwent screening transesophageal echocardio-
graphy (TOE) and a contrast 64-slice cardiac CT scan within 7 days
of the planned procedure. Three-dimensional reconstruction of
the left atrium and LAA was performed from the CT scan using
Ensite Verismo software (St. Jude Medical, St. Paul, USA), to assist
with planning of the ablation and anatomical analysis of the LAA
takeoff and morphology [7]. Pre-procedural TOE was utilized to
exclude LAA thrombus and to assess suitability of the ostial
dimensions for closure with the Watchmans device [8].
2.2. Procedure
Antiarrhythmic drug (AAD) therapy was stopped 3 days prior.
Therapeutic warfarin therapy was continued uninterrupted. After
June 2013, dabigatran and rivaroxaban were continued unin-
terrupted for patients with persistent AF. Procedures were per-
formed under general anesthesia using a bifemoral venous
approach. Intracardiac echocardiography was utilized to guide
double transseptal puncture and the ablation phase of the proce-
dure. Intravenous heparin was administered prior to the ﬁrst
transseptal puncture with a target ACT of Z350 s [5].
Ensite NavX cardiac navigational system (St. Jude Medical, St.
Paul, USA) with image integration of the segmented cardiac CT
scan was utilized. A 20 mm decapolar circular mapping catheter
and an irrigated-tip ablation catheter were utilized for mapping
and radiofrequency ablation. Left and right-sided pulmonary vein
antral ring electrical isolation was performed in all patients to an
endpoint of complete pulmonary vein entrance and exit conduc-
tion block. Additional complex fragmented atrial electrogram
(CFAE) guided or linear left or right atrial ablation was indivi-
dualized according to requirements for persistent forms of AF or
for redo ablation procedures. Patients undergoing ablation for
persistent AF were cardioverted back to sinus rhythm following
pulmonary vein isolation7CFAE or linear ablation.
After completion of the ablation phase, TOE imaging was
commenced. The LAA was assessed for ostial width and depth,
once a mean left atrial pressure measurement of Z10 mmHg was
obtained. The more favorable transseptal sheath location was
retained and the second sheath withdrawn to the venous circu-
lation. Implant of a Watchmans device was then performed as
previously described [7], using the post-ablation maximum LAA
ostial width for device sizing. Patients were observed overnight in
a coronary care unit and discharged within 24 h of the procedure.
2.3. TOE imaging assessment
Multidimensional assessment of the LAA ostium and body was
performed intraprocedurally and at subsequent follow-up using
approximate TOE angles of 0°, 45°, 90°, and 135° (see Fig. 1). Peri-
device leaks were quantiﬁed in millimeters jet size from color ﬂow
imaging, and the location of the leak described according to which
quadrant of the ostium was affected. In each case, for the vertical
plane, a ‘superior’ and ‘inferior’ quadrant of the ostium was
identiﬁed; and for the horizontal plane, the other 2 quadrants
were termed ‘anterior’ and ‘posterior.’ It should be noted, however,
that the correct anatomical description of the horizontal plane
would depend on whether the LAA projects in an anterior or lat-
eral orientation i.e., if the LAA projected anteriorly, the 2 quadrantswould be identiﬁed as medial and lateral; for a laterally projecting
LAA, the 2 quadrants would be orientated anterior and posterior.
2.4. Patient follow-up
Recurrent persistent early atrial tachyarrhythmias lasting Z48 h
were generally treated with electrical cardioversion, guided by TOE
imaging. Follow-up TOE imaging was performed at 6 weeks to
reassess the Watchmans appearances and efﬁcacy of LAA ostial
occlusion, the persistence of any interatrial septal shunt and to
exclude pulmonary venous stenosis. At 3 months, if satisfactory TOE
follow-up study had been conﬁrmed, anticoagulation was dis-
continued and antiplatelet therapy (aspirin 100 mgþclopidogrel
75 mg) commenced for a further 3 months. Satisfactory LAA
occlusionwas deﬁned as satisfactory positioning of the device at the
ostium covering all trabeculated portions of the LAA with peri-
device ﬂow o5 mm [1,7]. Further TOE assessment was performed
at 6, and then 12 months, if any peri-device leak into the LAA was
noted at 6 weeks, or if clinically required. Clinical follow-up for
arrhythmia recurrence was performed at 3, 6, and 12, months (and
every 6 months thereafter). Arrhythmia recurrence was assessed by
patient symptom reporting, 12 lead ECG, and implanted cardiac-
rhythm device interrogation, where applicable. Holter monitoring
was performed at 12 months, and as required, to assess symptom
recurrence. Antiarrhythmic drug therapy was ceased at or after
3 months, according to physician and patient discretion.
2.5. Statistical analysis
Results were analyzed using SPSS software and expressed as
mean7standard deviation. Unpaired t tests and Chi-square cal-
culations were performed. A p value o0.05 was considered to be
statistically signiﬁcant.3. Results
3.1. Patient demographics
Ninety-eight patients underwent combined left atrial catheter
ablation and implant of a Watchmans device between February
2010 and March 2015. An additional 4 patients were excluded –
2 patients had LAA ostium dimensions 431 mm and proceeded
with catheter ablation alone; 2 patients were found to have per-
sistent LAA thrombus despite appropriate anticoagulation, of
whom 1 proceeded to surgical excision and oversew of the LAA.
Table 1
Demographic and clinical variables for patient group.
n¼98
Age (yrs) 65(77)
Females (n) 31(32%)
Paroxysmal AF (n) 56(57%)
Duration of AF (yrs) 7(77)
EHRA Score (n) 3.7(70.5)
CHA2DS2VASc (n) 2.6(71.0)
HAS-BLED (n) 1.9(70.8)
Diabetes (n) 16(16%)
Hypertension (n) 64(65%)
IHD (n) 14(14%)
CHF (n) 8(8%)
CVA (n) 28(29%)
EF(%) 61(78)
AF: Atrial Fibrillation, EHRA score: European Heart Rhythm Asso-
ciation score of AF-related symptoms, HAS-BLED: score for major
bleeding risk, IHD: Ischemic Heart Disease, CHF: Congestive Heart
Failure, CVA: prior stroke / TIA, EF: Ejection Fraction.
Table 2
CHA2DS2-VASc and HAS-BLED scores for patient group.
CHA2DS2-VASc score n¼98 HAS-BLED score n¼98
0 0 0 1
1 12 1 30
2 39 2 45
3 32 3 21
4 10 4 1
5 4 5 0
6 1 6 0
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of 6576 years (range 43–81) (Table 1). The group included 56
patients with paroxysmal, 27 with persistent, and 15 with long-
standing persistent forms of AF. The mean EHRA Score for AF-
related symptoms [7] was 3.770.5. Eighty-seven patients were
undergoing a ﬁrst time ablation procedure for AF and 11 patients
were undergoing a redo. The mean CHADS2 score was 1.571.0
(range 0–4) and mean CHA2DS2-VASc score was 2.671.0 (range 1–
6) (Table 2), with 28 patients (29%) having a prior history of cer-
ebral or systemic thromboembolism. The mean HAS-BLED score
was 1.970.8 (range 0–4). All patients had been on established
anticoagulation prior to the procedure with 37 patients on war-
farin, 34 on dabigatran, and 27 on rivaroxaban. The indications for
LAA device occlusion were relative contraindications to long-term
oral anticoagulation in 29 (31%) (requirement for concomitant
antiplatelet therapy in 8, previous major bleeding in 8, comorbid
liver or renal disease in 2, alcohol abuse in 1, hazardous occupation
in 1, HAS-BLED score Z3 for other reasons in 10), systemic
thromboembolism or documented LAA thrombus despite ther-
apeutic oral anticoagulation in 5 (5%), and patient preference as an
alternative to indeﬁnite oral anticoagulation in 63 (64%).
3.2. Acute procedural success
Successful acute ablation endpoints were achieved in all patients,
including pulmonary vein electrical isolation and return to sinus
rhythm. Successful Watchmans implantation was achieved in all
patients. The mean total procedure time was 213740 min (range
120–330). The mean ﬂuoroscopic time was 36711 min (range 17–
65) and radiation dose area product (DAP) 16713 Gy cm2 (range 3–
77). The procedure was performed on uninterrupted warfarintherapy in 37 patients, uninterrupted rivaroxaban in 22, and unin-
terrupted dabigatran in 14. In the remaining 25 patients, dabigatran
(12/25) and rivaroxaban (13/25) were discontinued 1 day prior to the
procedure and recommenced 4 h post-procedure.
3.3. Acute procedural complications
Two patients were noted to have transient ST segment elevation
on ECG during Watchmans implantation, indicative of probable air
embolism, but no hemodynamic instability or subsequent clinical
sequelae were detected. Five patients were noted to develop simple
hematomas at the site of vascular access before discharge, which
resolved with conservative management. There were no other acute
procedural complications, in particular, no pericardial effusion,
stroke, or device embolization. All patients were discharged within
24 h of the procedure. One patient on uninterrupted rivaroxaban
was readmitted within 5 days with minor bleeding from the vas-
cular access site, which settled with conservative management.
3.4. LAA ostial assessment
In patients undergoing ﬁrst-time pulmonary vein isolation,
edema of the proximal ridge, between the left pulmonary veins
and LAA opening, was typically noted on TOE following ablation,
as compared with the pre-procedural study (Fig. 2). Ostial
dimensions at the planned level of LAA device occlusion differed in
31 of 98 patients from the pre-procedure to post-ablation TOE. In
15 of the 31 patients, the maximal LAA ostial dimension was
smaller post-ablation (range 1–8 mm), and in 16 patients, the
dimension was larger post-ablation (range 1–3 mm).
3.5. Acute LAA device occlusion
Complete occlusion of the LAA was achieved with the Watch-
mans device in 92 patients, and a small peri-device leak ranging
from 1 to 4 mm accepted in 6 patients at implant. The location of
the leak was posterior in 5 patients (best viewed in TOE 135° or
45° angle), and inferior in 1 patient (TOE 90° angle). The leak was
associated with device angulation that could not be corrected for
in 2 patients and with device ‘shoulder’ protrusion in 4 patients.
The mean maximal LAA ostium diameter at the time of implant
was 20.673 mm (range 14–28), and mean deployed device size
2473 mm (range 21–30). The mean minimum device compres-
sion measurement was 1575% (range 8–24%). The mean number
of devices used per procedure was 1.0370.2 (1 device used in 95
patients, 2 devices required in 3).
3.6. TOE follow-up
All patients had satisfactory Watchmans appearances and
occlusion of the LAA (peri-device leak o5 mm) [1,7] at 6 weeks'
follow-up. Thirty-two of the 98 patients had further TOE studies at
6 months, and 10 patients at 12 months, to re-evaluate the pro-
gress of peri-device leaks. No pulmonary venous stenosis was
detected. The interatrial septum had healed with no residual
detectable interatrial shunt in 82% (80/98) at the 6-week follow-
up. Incidental, asymptomatic device-associated thrombus was
detected in two patients: one at the routine 6-week study and
another 1-week post-implant at a TOE study performed to guide a
proposed DC cardioversion. In both cases, the seating of the device
appeared appropriate and no peri-device leak was detected. The
thrombus was demonstrated to resolve without clinical sequelae
on continued rivaroxaban therapy over the next 4 months in the
ﬁrst case, and on continued dabigatran therapy by 6 weeks post-
implant in the second case.
Fig. 2. Panel of images showing appearances of ridge between left superior pul-
monary vein and left atrial appendage (arrowed) before ablation in panel A and
edematous after ablation in panel B. In panel C the position of the Watchmans
device (arrowed) after deployment is distal to the edematous region. Labels indi-
cate LSPV (left superior pulmonary vein).
Fig. 3. Panel of images showing Watchmans device seating issues that were
associated with late persistent peri-device leaks. Panel A shows angulation of the
Watchmans device in relation to the long axis of the LAA; panel B shows sig-
niﬁcant device ‘shoulder’ protrusion above the ostium (arrowed); panel C
demonstrates with color ﬂow imaging a 2 mm peri-device leak (arrowed) asso-
ciated with the ‘shoulder’ protrusion.
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3.7.1. Persistent peri-device leaks from implant
The peri-device leaks from implant resolved in 2 patients and
persisted in 4 patients at follow-up, either reducing in size or
remaining consistent. The location of the persistent leaks was
posterior in all (best viewed in TOE 135° or 45° angle). Thepersistent leaks from implant were associated with device angu-
lation in 2 patients, and device ‘shoulder’ protrusion in 2 (Fig. 3).
3.7.2. New peri-device leaks at follow-up
Twenty-eight new peri-device leaks were detected at the
6 week TOE (range 1–3 mm), with 18 of the leaks resolving again
by the 6 month follow-up, and 10 having a small persistent leak
(1–2 mm) at 12 month follow-up. The anticoagulation regimen in
the 28 patients with new peri-device leaks at the 6-week follow-
up was warfarin in 29%, dabigatran in 39% and rivaroxaban in 32%.
The location of the new peri-device leaks were posterior in 79%
(best viewed in TOE 135° angle), inferior in 18% (TOE 90° angle),
and anterior in 4% (TOE 45° angle) (po0.0001) (Fig. 4). New peri-
Fig. 4. Panel of images from a patient who developed a transient peri-device leak
at 6-week follow-up TOE study. Panel A is an internal view of LAA ostium from
cardiac CT reconstruction demonstrating elliptical oriﬁce; panel B is a 3D TOE
image of Watchmans device at time of implant showing complete occlusion of
ostium; panel C is a 3D TOE image of Watchmans device at 6 week follow-up
showing crescentic 2 mm leak at inferior margin (red arrow) associated with the
largest LAA dimension. Labels indicate LSPV (left superior pulmonary vein), LIPV
(left inferior pulmonary vein), LAA (left atrial appendage), and MA (mitral annulus).
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(inferior and posterior locations) and device ‘shoulder’ protrusion
in 32% (posterior location in 8, anterior location in 1), but in the
remainder, the device appeared well seated. In 5 of the 28 patients
with a new peri-device leak, a measurement discrepancy was
found between the screening and post-ablation TOE ostial dia-
meter: in 2 patients, the dimensions were larger than the
screening TOE (range 1–3 mm) and in 3 patients, the dimensions
were smaller (range 1–3 mm).
The location of the persistent late leaks from the ‘new peri-
device leak’ group was posterior in 70%, inferior in 20%, and anterior
in 10%. Persistent late leaks from the ‘new peri-device leak’ group
were associated with device angulation in 40% (inferior and pos-
terior locations) and/or device ‘shoulder’ protrusion in 60% (pos-
terior and anterior locations). This contrasted with the group with
transient ‘new peri-device leaks’ (in whom the leak subsequently
resolved), whereby device angulation was only detected in 6% and
shoulder protrusion seen in 17% (p¼0.004 vs. persistent leaks).
3.7.3. Device compression
The mean device compression achieved in all patients with all
persistent late leaks (n¼14) was 1273%, as compared with
1575% (po0.01) in patients with complete LAA occlusion.
3.7.4. Twelve month LAA occlusion
The 12-month complete LAA occlusion rate was 86% (84/98) for
the group, with satisfactory results achieved in the remainder,
with peri-device leaks ranging from 1 to 2 mm.
3.8. Clinical follow-up
No patient was lost to follow-up. The mean follow-up time for
the series was 8027439 days (range 88–1932). One female
patient, on warfarin, was transferred back from a regional hospital,
with progressive congestive cardiac failure (dyspnea and marked
peripheral edema) 37 days after the procedure following early,
severe pericarditis symptoms. She was found to have a large
pericardial effusion, which required pericardiocentesis. She was
diagnosed with effusive pericarditis (presumed due to the cardiac
ablation) [9], and also received a course of prednisone and col-
chicine, subsequently making an uneventful recovery.
3.8.1. Arrhythmia events
Ninety-ﬁve of 98 patients were in sinus rhythm at the
3 months' follow-up, and anticoagulation was discontinued in 94
of 95 patients at this time, with 1 patient remaining on rivarox-
aban until 6 months because of device-associated thrombus. Three
of 98 patients were in persistent AF at 3 months follow-up and
continued oral anticoagulation for the purposes of repeated elec-
trical cardioversion. Two of the three patients with recurrent
persistent AF subsequently accepted permanent AF. Oral antic-
oagulation was subsequently discontinued and substituted with
antiplatelet agents in all 98 patients. Beyond 6 months' follow-up,
90 patients were prescribed aspirin only and 8 patients remained
on dual antiplatelet therapy, due to drug-eluting coronary stents
or history of recurrent myocardial infarction on aspirin.
At 3 months' follow-up, absence of detectable atrial tachy-
cardias/atrial ﬁbrillation (AT/AF) was noted in 75/98 (76%). For
patients with at least 12 months follow-up, the 1-year rate of
freedom from detectable AT/AF was 62/80 (77%). The 1 year rate of
freedom from detectable AT/AF for patients with paroxysmal AF
was 38/46 (83%), with 13/46 electing to remain on AAD, 17/23
(74%) for patients with recent persistent AF (15/23 patients
remained on AAD), and 7/11 (64%) patients with longstanding
persistent AF (10/11 patients remained on AAD). The mean EHRA
score at follow-up was 1.370.5. Eleven patients subsequently
Fig. 5. Post-mortem photo of Watchmans device 5 months post-implant sub-
sequent to concomitant catheter ablation and implant procedure. Complete
occlusion of the LAA ostium was noted with almost complete endothelialisation of
the device surface (small gap in endothelialisation noted at 8 o'clock).
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recurrence (recommencing oral anticoagulation peri-procedure),
with subsequent freedom from arrhythmia in 9. For patients with
at least 2-years clinical follow-up (50/98), the late freedom from
detectable AT/AF was maintained in 32/50 (64%) at a mean follow-
up time of 11437307 days.
3.8.2. Electrical cardioversion
Over the period of follow-up, 13 patients underwent electrical
cardioversion for recurrent, persistent atrial tachyarrhythmia,
ranging from 9 days to 18 months after the index procedure.
Patients were continued on, or recommenced, on oral antic-
oagulation for 4 weeks, following electrical cardioversion. TOE
guidance was performed if the cardioversion was planned prior to
the initial 6-week follow-up imaging study. Seven patients
underwent TOE guided ‘early’ electrical cardioversion within the
ﬁrst 6 weeks with no detectable dislodgement of the Watchmans
device at the time of the procedure or at subsequent follow-up.
3.8.3. Stroke events
One patient (CHA2DS2-VASc score of 5) represented 24 months
post-implant with a left frontal cortical acute ischemic stroke
conﬁrmed on serial CT scans of the brain. Pacemaker interrogation
conﬁrmed that the patient remained free of atrial tachyarrhythmia
since the procedure. TOE study showed satisfactory appearance of
the Watchmans device, with a 2 mm peri-device leak unchanged
since implant. Complex aortic atheroma was noted on TOE and
moderate carotid atheroma was detected on carotid ultrasound.
The patient had a prior history of myocardial infarction and
reported having stopped atorvastatin therapy six weeks prior. The
attending neurologist judged the stroke to be atherothrombotic in
cause. Oral anticoagulation was not recommenced. Routine neuro-
radiological evaluation was not performed to examine for sub-
clinical events in other patients. The observed ischemic stroke rate
for the group was 0.5% per year.
3.8.4. Deaths
One patient was deceased at 5 months post-procedure from
suicide. The coronial report did not implicate the procedure in the
cause of death. The post-mortem ﬁndings showed no cardiac
thrombus, with almost complete endothelialization of the device
surface (Fig. 5).4. Discussion
The results of this retrospective study demonstrate the feasi-
bility and safety of combined left atrial catheter ablation and
Watchmans implant procedures with satisfactory LAA occlusion
maintained at follow-up. The rates of successful device implanta-
tion and complete LAA occlusion at follow-up in the current study
compare favorably with results from the larger randomized con-
trolled trials evaluating Watchmans implantation versus warfarin
therapy [1]. The rates of successful device implantation were 91%
in PROTECT-AF [7] and 95% in PREVAIL [10] as compared with
100% in our series. The 12 month rates of complete LAA occlusion
on TOE studies in PROTECT-AF was 68% [11] as compared with 86%
in this study.
Ablation-induced tissue injury at the ostium of the LAA follow-
ing left pulmonary vein isolation was frequently observed on TOE
during the procedures. However, the level of occlusion with the
Watchmans device was always distal to any observed edematous
change. Variation in the maximal measured LAA ostial dimension
between the pre-procedure and the post-ablation TOE was
observed in around one third of patients. However, this did not
impact appropriate device sizing or rates of incomplete occlusion.The development of ‘new,’ small peri-device leaks at the initial
follow-up TOE has also been observed in 12–13% of patients in
other Watchmans series [12,13], although, the rate was sig-
niﬁcantly higher in our study. The phenomenon is possibly related
to a mismatch between the circular device and typical elliptical
oriﬁce of the LAA, that might be partially masked by an edema
response at the time of implant. In the current series, the most
common location for new leaks was at the posterior margin of the
LAA ostium (best viewed in TOE angle 135°), which is commonly
the largest dimension of the ostium (Fig. 1). Reassuringly, the
majority of these new leaks were observed to resolve at follow-up,
and the 12-month complete occlusion rate of 86% in our study was
comparable to that in the other small series (93% and 66%). In our
series, late persistent leaks were more frequently associated with
device angulation or shoulder protrusion, suggesting that sub-
optimal device seating or apposition with the LAA walls is impli-
cated. A statistically signiﬁcantly lower amount of device com-
pression was also noted for persistent late leaks as compared with
complete occlusion (1273% vs. 1575%), suggesting that, where
feasible, oversizing of the device by Z15% may be preferred.
Concern has been raised that residual peri-device leaks have
the potential to further enlarge with time in patients with
untreated AF [13]. Progressive atrial dilatation as a consequence of
AF is widely recognized [14] – progressive dilatation of the LAA
ostium may also occur [6]. Reversal of left atrial dilatation in
patients maintaining sinus rhythm following successful catheter
ablation is also well documented [15]. This may be beneﬁcial for
patients undergoing the combined procedure with Watchmans
device implantation, with the potential for reverse remodeling to
shrink the LAA ostium around the implanted device. Further study
is required to evaluate the effects of longer term atrial remodeling
in different AF populations undergoing LAA device occlusion pro-
cedures. Fortunately, the evidence to date suggests that small
residual peri-device leaks are unlikely to compromise the efﬁcacy
of LAA occlusion devices [16,17].
A signiﬁcant number of the procedures were performed on
patients on uninterrupted warfarin with a therapeutic INR. The
safety of this approach has been documented for patients under-
going catheter ablation procedures for AF [18]. This series suggests
this is also a safe approach for patients undergoing percutaneous
LAA device occlusion. A small number of procedures were also
performed on uninterrupted, novel oral anticoagulants. Further
experience with performing catheterization procedures on the
novel oral anticoagulants is required before drawing conclusions
about the safety of this approach. Asymptomatic, early device-
K.P. Phillips et al. / Journal of Arrhythmia 32 (2016) 119–126 125associated thrombus was also noted in 2 patients (2%) in this study
– both on novel anticoagulants (1 on dabigatran and 1 on rivar-
oxaban). However, the incidence was not signiﬁcantly different
from that reported in the PROTECT AF trial (3%) using warfarin
[16]. Overall, the current experience supports the use of the novel
anticoagulants with the Watchmans prosthesis as safe.
The results from catheter ablation in this cohort were com-
parable to previously reported outcomes [2,3]. The majority of
patients with persistent or longstanding persistent AF, however,
did not discontinue antiarrhythmic drug therapy post-procedure
as an adjunctive measure to improve long-term maintenance of
sinus rhythm. This strategy is aimed at reducing the signiﬁcantly
elevated long-term late recurrence rates associated with persistent
AF [3]. The strategy is informed by demonstration of the relative
safety of antiarrhythmic drug use in a patient populations
receiving appropriate stroke prevention [19]. The presence of the
Watchmans implant did not appear to impact the subsequent left
atrial ablation procedure in patients requiring a redo, although, the
repeat procedure was deferred at least 6 months to allow for
implant healing [20].
In this case series, no clinical thromboembolic events were
detected in a cohort with a mean CHA2DS2-VASc score of 2.6 71
over a follow-up time of up to 5 years. The overall stroke rate was
0.5% per year. The authors concede that the very low stroke rate
could have been the outcome of successful ablation and freedom
from AF in the majority of patients. A body of evidence now points
to catheter ablation therapy for AF conferring stroke risk reduction
[21,22]. However, AF recurrence, cardiovascular morbidity, and
stroke, are still observed to correlate with CHA2DS2-VASc score of
2 or greater over long-term follow-up [21–23]. The stroke rate in
the current study compares similarly with the 0.72% event rate at
mid-term follow-up of a large cohort of patients on anticoagulants
with a mean CHA2DS2-VASc score of 2.171.4 from the Leipzig
Heart Center AF Ablation Registry [22] and contrasts with a much
higher reported event rate of 5.1% for patients with CHA2DS2-VASc
score of 2 who did not receive anticoagulation over a follow-up
period of 39 months following catheter ablation [23]. This suggests
that the two-pronged strategy may provide long-term cardiovas-
cular beneﬁts to patients with non-valvular AF, that is at least
equivalent to ongoing oral anticoagulation strategy for patients
with a CHA2DS2-VASc score of 2 or greater.
While the long-term follow-up of Watchmans-implanted
patients in the PROTECT-AF randomized -controlled trial demon-
strated superiority over warfarin for all cause stroke and mortality
[1], concern has been raised over sub-analysis of the more recently
conducted PREVAIL trial which showed a relatively higher rate of
ischemic strokes during follow-up in the Watchmans group [10].
The single case of late ischemic stroke in the current study points
to the difﬁculty of judging the mechanism of stroke in a patient
group that frequently also has risk factors for atherothrombotic or
hypertensive occlusive events. The authors are encouraged by the
patient outcomes of the current series, and believe that catheter
ablation for AF and LAA device occlusion will be complementary to
a multi-faceted approach to long-term stroke prevention. How-
ever, further randomized controlled trials are required to deﬁne
their respective roles.
4.1. Study limitations and future directions
One of the limitations of the current study, and other Watch-
mans implant series, is the lack of longer-term longitudinal ima-
ging follow-up of all Watchmans implants. It is currently pre-
sumed that once complete occlusion (and tissue ingrowth over the
prosthesis) is achieved, that complete occlusion will be indeﬁ-
nitely maintained. Further studies using TOE or contrast CT scan
are required to document extended outcomes.5. Conclusions
Combined procedures of catheter ablation for atrial ﬁbrillation
and percutaneous closure of the left atrial appendage with the
Watchmans device were efﬁcacious and safe in our single center
experience with excellent rates of LAA occlusion achieved and an
observed stroke rate of 0.5% per year during mid-term follow-up.
Incomplete occlusion was associated with lower achieved device
compression, and was more frequently associated with suboptimal
device position, such as angulation and shoulder protrusion.Conﬂict of interest
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